Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
暂无分享,去创建一个
A. Reuss | H. Mackay | A. Oza | N. Colombo | A. du Bois | M. Brady | M. Bookman | E. Pujade-Lauraine | N. Siddiqui | A. Swart | J. Pfisterer
[1] R. Ozols,et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Reuss,et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. , 2006, Journal of the National Cancer Institute.
[3] M. Bookman,et al. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Kimmig,et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Trimble,et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. du Bois,et al. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. , 2005, Gynecologic oncology.
[7] S. Rubin,et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.
[8] Alan Gordon,et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.
[9] M. Gore,et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Bauknecht,et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.
[11] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Tannock,et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.
[13] T. Kanoh,et al. [A group study on prognosis of ovarian cancer in Japan]. , 1992, Nihon Sanka Fujinka Gakkai zasshi.
[14] D. Gersell,et al. Metastatic ovarian tumors: still a challenge. , 1992, American journal of clinical pathology.
[15] E. Yordan,et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Gershenson,et al. Mucinous tumors of the ovary. A clinicopathologic study of 70 cases , 1985, Cancer.
[17] A. Parwani. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .
[18] M. McKay,et al. Cancer of the ovary. , 1994, The New England journal of medicine.
[19] T. Parmley,et al. Interobserver variability in the interpretation of epithelial ovarian cancer. , 1984, Gynecologic oncology.